Target Price | $25.11 |
Price | $14.81 |
Potential |
69.52%
register free of charge
|
Number of Estimates | 19 |
19 Analysts have issued a price target ACADIA Pharmaceuticals Inc. 2025 .
The average ACADIA Pharmaceuticals Inc. target price is $25.11.
This is
69.52%
register free of charge
$39.00
163.34%
register free of charge
$12.00
18.97%
register free of charge
|
|
A rating was issued by 20 analysts: 13 Analysts recommend ACADIA Pharmaceuticals Inc. to buy, 6 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the ACADIA Pharmaceuticals Inc. stock has an average upside potential 2025 of
69.52%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 726.44 | 952.48 |
40.45% | 31.12% | |
EBITDA Margin | -9.34% | 8.98% |
78.20% | 196.17% | |
Net Margin | -8.45% | 9.42% |
80.34% | 211.52% |
20 Analysts have issued a sales forecast ACADIA Pharmaceuticals Inc. 2024 . The average ACADIA Pharmaceuticals Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an ACADIA Pharmaceuticals Inc. EBITDA forecast 2024. The average ACADIA Pharmaceuticals Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
16 ACADIA Pharmaceuticals Inc. Analysts have issued a net profit forecast 2024. The average ACADIA Pharmaceuticals Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.37 | 0.54 |
72.39% | 245.95% | |
P/E | 27.39 | |
EV/Sales | 2.11 |
16 Analysts have issued a ACADIA Pharmaceuticals Inc. forecast for earnings per share. The average ACADIA Pharmaceuticals Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the ACADIA Pharmaceuticals Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
ACADIA Pharmaceuticals Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.